Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer
2023-507263-19-00Phase 3Authorised
- Sponsor
- Mirati Therapeutics
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adagrasib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Planned start Dec 2020; status: authorised.
02
Drugs
adagrasibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507263-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507263-19-00.